EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir–Velpatasvir

Alessio Aghemo, Alessia Ciancio iD, Ernesto Claar, Nicola Coppola iD, Alessandra Mangia, Marco Riglietta iD, Massimo Puoti

Viruses · 2026

DOI: 10.3390/v18080854 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2026. Verfasst von Alessio Aghemo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, Sofosbuvir, Carbamates, Heterocyclic Compounds, 4 or More Rings. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences (Italy).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: Hepatitis C virus (HCV) infection often coexists with comorbidities, increasing vulnerability, complications, and adverse events. Direct-acting antivirals (DAAs) have dramatically improved HCV management, but they differ in drug–drug interaction (DDI) profiles. Sofosbuvir/velpatasvir (SOF/VEL) is associated with minimal clinically relevant interactions. Areas covered: A narrative review of the literature was conducted by searching PubMed and major international guidelines, focusing on studies published in the DAA era addressing HCV patients with major comorbidities, focusing on diabetes, metabolic syndrome, and cardiovascular disease; neuropsychiatric disorders; cancer; transplants; and use of substances or treatment with opioid agonists; and patients requiring hormone therapy including transgender patients. Expert opinion: Based on the literature and real-world data, managing polypharmacy in HCV patients with comorbidities is effective and well-tolerated, provided thorough drug review, potential DDI analysis, proactive monitoring, and coordinated multidisciplinary care are ensured. DAAs have dramatically improved the management of HCV patients; however, they have different DDI profiles that should be carefully checked. SOF/VEL has been shown to be associated with minimal clinically relevant interactions and offers a simple dosing regimen. DAA treatment is strongly advised in HCV comorbid patients not only to cure HCV but also to improve the course of comorbidities, provided that DDIs are no longer considered mere minor details.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSofosbuvirCarbamatesHeterocyclic Compounds, 4 or More RingsHepatitis CHepatitis C, ChronicHumansDrug InteractionsComorbidityBenzopyransHepacivirusBenzimidazolesPolypharmacyDrug Combinations

Stichwörter der Autor:innen

HCV infectioncomorbiditiesdirect-acting antiviralsdrug–drug interactionspolypharmacysofosbuvir/velpatasvir

Substanzen

Antiviral AgentsSofosbuvirCarbamatesHeterocyclic Compounds, 4 or More RingsBenzopyransBenzimidazolessofosbuvir-velpatasvir drug combinationDrug Combinations

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy.
  • Division of Internal Medicine and Hepatology, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.
  • A.O.U. Città della Salute e della Scienza di Torino, 10126 Torino, Italy.
  • Ospedale Evangelico Villa Betania, 80147 Napoli, Italy.
  • Dipartimento di Salute Mentale e Fisica e Medicina Preventiva, Università degli Studi della Campania "Luigi Vanvitelli", 80133 Napoli, Italy.
  • IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy.

ORCID-Profile: Alessia Ciancio, Nicola Coppola, Marco Riglietta

Förderung

  • Gilead Sciences (Italy)

Zitieren

APA

Aghemo, A., Ciancio, A., Claar, E., Coppola, N., Mangia, A., Riglietta, M., & Puoti, M. (2026). Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir–Velpatasvir. Viruses. https://doi.org/10.3390/v18080854

Vancouver

Aghemo A, Ciancio A, Claar E, Coppola N, Mangia A, Riglietta M, et al. Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir–Velpatasvir. Viruses. 2026. doi:10.3390/v18080854

BibTeX
@article{Aghemo2026,
  author = {Aghemo, Alessio and Ciancio, Alessia and Claar, Ernesto and Coppola, Nicola and Mangia, Alessandra and Riglietta, Marco and Puoti, Massimo},
  title = {Direct-Acting Antivirals in Patients with Comorbidities for the Simplified Management of HCV Infection: An Expert Review with a Focus on Sofosbuvir–Velpatasvir},
  journal = {Viruses},
  year = {2026},
  doi = {10.3390/v18080854}
}
Kostenlos starten →